MERCK & CO., INC.
NYSE: MRK
▲
92.42
+1.25
+1.37%
1 Day
-
Open
91.30
-
Previous Close
91.17
-
Volume (Avg)
11.41M (13.27M)
-
Day's Range
90.39-92.49
-
52Wk Range
70.89-95.72
-
Market Cap.
233.71B
-
Dividend Rate (Yield)
2.76 (3.03%)
-
Beta
0.36
-
Shares Outstanding
2.53B
-
P/E Ratio (EPS)
16.62 (5.48)
Top Stories
-
Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA
Zacks.com 11 hrs ago -
Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill
Zacks.com -
Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs
Zacks.com -
Merck To Start Pivotal Trial For Next-Gen Pneumococcal Vaccine Next Month
Benzinga -
AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer
Zacks.com 3 days ago -
Merck's (MRK) Pneumococcal Vaccine Gets FDA Nod for Kids
Zacks.com -
3 Top Dividend Stocks for Generating Passive Income
The Motley Fool -
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
Zacks.com -
Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration
Zacks.com -
Pfizer asks for full FDA approval of COVID pill
The Hill -
Coronavirus Alert
Everyday Health -
DEM BioPharma launches with $70m to take a bite out of cancer
The Boston Globe -
Foods You Should Eat If You Need More Calcium
Health Digest -
Dow's 131-point climb led by gains for shares of UnitedHealth, Johnson & Johnson
MarketWatch -
At a Bay Area ‘test-to-treat’ site, few takers for free antivirals
San Francisco Chronicle 6/18/2022 -
European Markets Move Higher as Growth Fears Remain
Investing.com -
COVID-19 Test to Treat program is making treatment accessible for everyone
Tucson (Sierra Vista) KOLD -
Why isn’t Mark Cavendish at the Tour de France 2022? Manx Missile misses chance to pass Eddy Merckx’s record
The i
